Another step towards improving oncofertility counselling of young women with Hodgkin's lymphoma by Lambertini, Matteo & Demeestere, Isabelle
Comment
1264 www.thelancet.com/oncology   Vol 19   October 2018
instead be invested in smarter clinical trial designs 
that can answer relevant clinical questions, such as 
whether sequencing of drugs is better than combination 
therapies, or defining the optimal duration of adjuvant 
treatment. One advantage of having so many 
different therapeutic options available from different 
pharmaceutical companies is that the possibilities for 
conducting such truly necessary clinical trials multiply. 
Fortunately, an embarrassment of riches.
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Possible chemotherapy-induced premature ovarian in-
sufficiency is of great concern for female premenopausal 
patients with cancer. Therefore, appropriate counselling 
on the risk of premature ovarian insufficiency is now 
mandatory in all countries.1,2 Oncofertility counselling 
is of particular importance for women who have 
Hodgkin’s lymphoma, who are often diagnosed at a 
young age. However, the counselling of these women 
can be quite complex because of the paucity of accurate 
data to estimate the effect of different chemotherapy 
regimens on their gonadal function. Previous studies in 
this setting were mostly retrospective or relied only on 
menstrual function after treatment to define premature 
ovarian insufficiency, a measure that is not an optimal 
surrogate for assessing gonadal damage associated with 
treatment.
In The Lancet Oncology, Richard A Anderson and 
colleagues3 report important results for helping physi-
cians informing premenopausal women with advanced 
Hodgkin’s lymphoma about the risk of chemotherapy-
induced premature ovarian insufficiency associated with 
doxorubicin, bleomycin, vinblastine, and dacarbazine 
(ABVD) or AVD, or bleomycin, etoposide, doxorubicin, 
cyclophosphamide, vincristine, procarbazine, and pred-
nisone (BEACOPP) chemotherapy.3 In this substudy, 
done within the RATHL trial (NCT00678327), biomarkers 
of ovarian function during and up to 3 years after 
chemotherapy were assessed in women younger 
than 45 years at the time of diagnosis. Specifically, 
67 participants were monitored for serum antimüllerian 
hormone concentrations and 321 participants for 
follicle-stimulating hormone concentrations 
Despite a few limitations, including the small sample 
size of the antimüllerian hormone analysis, particularly 
of those who were treated with BEACOPP, and the 
lack of collection of participant information from the 
main RATHL cohort that could have had a potential 
effect on outcomes (eg, use of hormonal contraceptives, 
previous fertility preservation procedures, and men-
strual status after chemotherapy), this study provides 
more precise information than previous reports to 
counsel women with Hodgkin’s lymphoma on gonadal 
damage induced by ABVD, AVD, or BEACOPP. The results 
from this study raise several factors for consideration by 
patients and physicians. 
First, the study confirms that both the type of 
chemotherapy and patient’s age at the time of 
treatment remain the two major determinants of 
risk of premature ovarian insufficiency for all patients 
with cancer.4,5 Antimüllerian hormone concentrations 
decreased sub stantially during both chemotherapy 
regimens; however, while antimüllerian hormone 
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concentrations recovered to before treatment levels 
in those patients given ABVD or AVD by 1 year after 
treatment, little recovery of antimüllerian hormone 
concentrations was seen after treatment with 
BEACOPP.3 In Anderson and colleagues’ study, age 
was shown to be a crucial factor, with increased risk of 
chemotherapy-induced premature ovarian insufficiency 
after both regimens in women aged 35 years and older 
at the time of diagnosis.
Second, these results highlight the need for a 
standardised definition of premature ovarian insuf-
ficiency. Different endpoints (menstrual function only, 
ovarian biomarkers only—as in the present study—or a 
combination of the two) and timing of its assessment 
(ranging from a few months up to several years after 
chemotherapy) have been used to define chemotherapy-
induced premature ovarian insufficiency. Therefore, 
cross-study comparisons remain difficult, even when 
the same chemotherapy regimens have been assessed. 
Guidelines suggest use of a composite endpoint that 
includes both amenorrhoea and a hormone profile after 
menopause,6,7 and assessing chemotherapy-induced 
pre mature ovarian insufficiency at least 2 years after 
the end of treatment.7 In the present study, recovery of 
ovarian function, as measured by follicle-stimulating 
hormone concentrations, occurred by 1 year after 
the end of treatment for most patients (75% treated 
with ABVD or AVD and 33% treated with BEACOPP), 
but recovery can also happen during the second year 
(18% of participants treated with ABVD or AVD and 
50% with BEACOPP) with little chance of recovery 
thereafter. These results support the expert opinion-
based indication to assess ovarian function after 
chemotherapy no earlier than 2 years after treatment 
completion.7 
Third, although this study provides further evidence 
on the role of antimüllerian hormone as a biomarker 
of gonadotoxicity, the clinical utility of its assessment 
during treatment and subsequent follow-up remains to 
be fully determined. As shown in other studies,8,9 both 
resumption of menstrual function and spontaneous 
conception can be observed in women with low 
concentrations of antimüllerian hormone.8,9 Similarly, 
in Anderson and colleagues’ study,3 some pregnancies 
were observed in women with very low antimüllerian 
hormone levels. Hence, the best predictor of infertility in 
cancer survivors remains to be identified.
Finally, this study raises the crucial issue of discussing 
the possibility of reducing the risk of premature ovarian 
insufficiency.1,2 Preservation of ovarian function (ie, 
reducing the risk of chemotherapy-induced premature 
ovarian insufficiency) should be distinguished from 
preservation of fertility (ie, improving the chances of 
pregnancy after treatment) and can be considered of 
important value also by women without childbearing 
desire. While cryopreservation of gametes is the first 
option to preserve fertility, the use of temporary ovarian 
suppression with gonadotropin-releasing hormone 
agonists during chemotherapy can now be offered for 
ovarian function preservation in patients with breast 
cancer, but its efficacy has not yet been shown in patients 
with Hodgkin’s lymphoma.9,10 The results of Anderson 
and colleagues’ study highlight the importance of 
discussing access to these options in women older than 
35 years, irrespective of chemotherapy type, and among 
candidates to the BEACOPP regimen, irrespective of 
their age. Very young women undergoing ABVD or 
AVD chemotherapy probably do not need to access 
these options, but they could be proposed later in life if 
additional treatments are required.
Results from the ovarian function biomarker analysis 
ongoing within the AHL 2011 trial (NCT01358747) 
are awaited to provide further evidence on the 
gonadotoxicity of BEACOPP chemotherapy in premeno-
pausal women with Hodgkin’s lymphoma.
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Camrelizumab for nasopharyngeal carcinoma: a new hope?
Wenfeng Fang and colleagues1 report on two phase 1 
studies of the programmed cell death-1 (PD-1) inhibitor, 
camrelizumab (SHR-1210), as a treatment for patients 
with recurrent or metastatic nasopharyngeal carcinoma. 
The first trial tested camrelizumab monotherapy in 
93 patients who received at least one previous line of 
treatment for recurrent or metastatic nasopharyngeal 
carcinoma. The second trial tested camrelizumab in 
combination with gemcitabine and cisplatin as a first-
line treatment in 23 treatment-naive patients with 
the same diagnosis. Both trials showed good safety 
profiles with no treatment-related deaths observed 
in patients treated with camrelizumab monotherapy 
or camrelizumab combined with chemotherapy. 
The more interesting findings are the preliminary 
antitumor activity of camrelizumab in both settings: 
31 (34%; 95% CI 24–44) of 91 patients who received 
previous treatment  achieved an overall response 
with camrelizumab monotherapy (two patients had 
a complete response) and 20 (91%; 77–97) of 22 patients 
with the combination of camrelizumab and chemotherapy 
as first-line treatment (one patient had a complete 
response). These results are the most promising so far 
reported for PD-1 inhibitors tested in nasopharyngeal 
carcinoma. 
Two previous studies reported on the preliminary 
antitumor activities of PD-1 inhibitors in patients 
with previously treated recurrent or metastatic naso-
pharyngeal carcinoma. The KEYNOTE-028 study2 showed 
that seven (26%; 95% CI 11·1–46·3) of 27 patients 
with previously treated, advanced disease achieved an 
objective response with pembrolizumab. The NCI-9741 
trial3 showed that nine (20·5%; 95% CI 9·8–35·3; one 
complete repsonse) of 44 patients with previously treated 
recurrent or metastatic naso pharyngeal carcinoma 
achieved an objective response with nivolumab. Further 
investigation of the underlying cause of the differences 
in activity (objective responses) reported in these three 
studies would be of interest. The difference might be 
due to the activity of each drug, but the mechanism of 
action appears very similar for different PD-1 inhibitors. 
Variations in patient populations, tumour biology, and 
previous treatments received might be also important 
especially for small patient cohorts. Both KEYNOTE-028 
and NCI-9741 are international studies including 
63% and 82·2% Asian patients, respectively; whereas 
the current study by Fang and colleagues1 was done in 
an endemic Chinese population. The proportion of WHO 
type 2 or 3 tumours in KEYNOTE-028 was 66·7%, 82·2% 
in NCI-9742, and 82% in the camrelizumab monotherapy 
trial of the current study. In terms of patient selection, 
KEYNOTE-028 only included patients with programmed 
cell death ligand-1 (PD-L1)-positive tumours, whereas 
both NCI-9742 and the current study enrolled patients 
with unselected histologies. In NCI-9742, 40% of patients 
had PD-L1-positive tumours, which was associated 
with an improved response (six [33%] of 18 patients) 
compared with PD-L1-negative tumours (three [13%] 
of 23 patients). PD-L1 positivity also appears to be 
predictive of response to PD-1 inhibitors in other head 
and neck squamous cell carcinomas.4,5 PD-L1 status was 
not reported by Fang and colleagues in the current study. 
Thus, the improvement in the frequency of objective 
responses might be affected by the proportion of patients 
with PD-L1-positive tumours in the study population. 
Interestingly, the study also found that six (75%) of eight 
patients who had previous treatment with ipilimumab 
and subsequent camrelizumab monotherapy achieved 
an objective response. This outcome might suggest that 
previous priming with ipilimumab could improve the 
